NutriDex

The Supplement Research Compendium

☠️

Phenibut

β-phenyl-γ-aminobutyric acid

A Soviet-era GABA-B drug sold online as a "calm" supplement — with a brutal dependence and withdrawal profile.

No Evidence evidence ☠️Banned & Harmful
Evidence tier
No Evidence
Research weight
Not supported
Citations
13 verified / 13
Classification
Banned & Harmful
What the evidence says. No credible human evidence supports the marketed claims — widely considered ineffective.
Health warning. Phenibut causes rapid tolerance and physical dependence, and abrupt cessation can trigger a severe, sometimes life-threatening withdrawal (delirium, hallucinations, seizures) — combining it with alcohol or other depressants can be fatal.

What is Phenibut?

Phenibut (β-phenyl-γ-aminobutyric acid) is a banned or harmful substance marketed for marketed for anxiety relief, but there are no rigorous, modern human trials demonstrating safe or effective use as a supplement — anxiolytic and sedative effects are mediated by gaba-b agonism but are unproven for any supplement claim and come with serious dependence risk.. NutriDex grades the human evidence as No Evidence. Phenibut (β-phenyl-GABA) is a central nervous system depressant developed in the Soviet Union that acts mainly as a GABA-B receptor agonist with additional gabapentinoid (α2δ calcium-channel) activity. It is sold online and in "supplement" or nootropic products for anxiety, sleep, and cognitive enhancement, but it is not approved as a dietary supplement or medicine in the US, UK, or Australia, and the FDA has stated it does not meet the definition of a dietary ingredient. There are no rigorous modern human trials supporting safe or effective supplement use, while a substantial case literature documents rapid tolerance, physical dependence, and a severe withdrawal syndrome that can include insomnia, hallucinations, agitation, delirium, and seizures, sometimes within hours of the last dose. Overdose — frequently involving co-ingested alcohol, benzodiazepines, or opioids — can cause profound sedation, reduced consciousness, agitated delirium, and cardiovascular and renal effects, with no specific antidote. Analyses have also found actual phenibut content in marketed products far exceeding label claims, compounding the risk. Given documented harms and absent credible benefit for its marketed claims, the evidence tier for safe supplement use is 'none'.

Marketed Claims (unproven)

Marketed for anxiety relief, but there are no rigorous, modern human trials demonstrating safe or effective use as a supplement — anxiolytic and sedative effects are mediated by GABA-B agonism but are unproven for any supplement claim and come with serious dependence risk.
Promoted for sleep and as a nootropic/cognitive enhancer; these claims are unsupported by credible controlled human evidence and are outweighed by documented harms.
Any short-term subjective calming or euphoric effect rapidly drives tolerance, escalating doses, and dependence rather than durable benefit.

Dosing & Compounds

Use & Legality
No safe or approved supplement dose exists. Illicit recreational use is commonly 250–1500 mg, but dependent users escalate dramatically (case-series average ~13.6 g/day); not recommended at any dose.
Active Compounds
Phenibut (β-phenyl-GABA), a GABA analog acting primarily as a GABA-B receptor agonistActivity at voltage-gated calcium channels (gabapentinoid-like α2δ activity) and weaker GABA-A effectsSold as racemic hydrochloride (HCl) and faah/free-acid (FAA) salt forms with differing potency per gram

Safety & Cautions

Not approved as a supplement or medicine in the US, UK, or Australia (banned/prohibited in Australia and restricted in several European countries). Phenibut produces rapid tolerance and physical dependence; abrupt cessation after regular use can cause a severe withdrawal syndrome — anxiety, insomnia, tremor, hallucinations, psychosis, autonomic instability, delirium, and seizures — that may require medically supervised baclofen or benzodiazepine tapering. Overdose causes deep sedation, reduced consciousness, agitation/delirium, low blood pressure, and renal impairment, with no specific antidote; high chronic intake (above ~7 g) has been linked to hepatic effects. Risk is greatly amplified by co-use with alcohol, benzodiazepines, opioids, or other CNS depressants — a common feature of reported toxicity and a potentially fatal combination. Marketed product potency is unreliable and often exceeds label claims, making dosing unpredictable. It must be avoided by anyone who is pregnant or breastfeeding, by people with a history of substance use disorder or psychiatric illness, and by those taking sedatives, GABAergics, or alcohol; do not stop established use abruptly — seek medical supervision. Educational only — always check with your doctor or pharmacist before combining Phenibut with any medicine.

Phenibut drug interactions

Known or theoretical interactions between Phenibut and common medications — educational, not exhaustive. Always check with your doctor or pharmacist before combining Phenibut with any medicine.

Avoid
Benzodiazepines, opioids, alcohol
Dangerous additive CNS and respiratory depression; risk of profound sedation and severe withdrawal.
Phenibut is a GABA-B agonist with CNS-depressant effects that compound other sedatives and alcohol. Ahuja — Phenibut withdrawal (systematic review)

Evidence & Risk Findings ★ 13 studies

Systematic review 62 cases / 36 studies ✓ Source
A 2023 systematic review of 62 phenibut toxicity/withdrawal cases found 80.7% were male (mean age ~31), 86.8% obtained phenibut online, and 63.2% reported concomitant use of other substances such as benzodiazepines, alcohol, or opioids.
Systematic review 15 case reports ✓ PubMed
A 2024 systematic review (Cureus) of 15 phenibut-withdrawal case reports found a mean daily dose of ~13.6 g (far above the 0.5–1.5 g 'recommended' range), with insomnia, hallucinations, and muscular symptoms each in 53% of cases; baclofen taper was the most effective management.
Systematic review Stewart 2024 (Cureus) ✓ Full text
Systematic review of 15 phenibut-withdrawal cases (mean age 31.8 yr, 87% male; mean dose 13.6 g/day) found withdrawal onset as early as 2 hours post-dose, with anxiety, agitation, insomnia, psychosis, delirium and seizures commonly managed with benzodiazepines and baclofen.
Systematic review J Addiction Medicine 2023 ✓ PubMed
Systematic literature review identified 62 cases across 36 studies of phenibut toxicity or withdrawal, summarizing clinical presentations (sedation, respiratory depression, agitation, psychosis) and treatment.
Systematic review Feldman et al. 2023 (PRISMA systematic review, 25 studies) ✓ PubMed
PRISMA systematic review of phenibut withdrawal: 100% male, median age 30 y, median daily dose 10 g (range 1-200 g); withdrawal onset as early as 2 h after last dose. Seizures in 8%, intubation in 24%, ICU admission in 44%; 76% required >=2 drug therapies. Benzodiazepines used in 68% and baclofen in 60%. Withdrawal severity was similar for mono- vs polysubstance use; no standardized treatment exists.
Regulatory statement regulatory statement ✓ Source
The US FDA states phenibut does not meet the statutory definition of a dietary ingredient and that any supplement declaring it is misbranded; in 2019 it issued warning letters to companies marketing phenibut-containing products as supplements.
Safety / toxicology Krzyzaniak 2024 (PMC) ✓ Full text
Report on phenibut as an illegal food supplement with psychotropic effects, documenting health risks including sedation, dependence and withdrawal associated with internet-sold products.
Narrative review narrative review ✓ Source
A 2024 review concludes phenibut is an unregulated GABA-B agonist whose online availability drives misuse, with no antidote and a recognized risk of dependence, severe withdrawal, and overdose, especially when combined with other CNS depressants.
Review Penzak & Bulloch 2024 (pharmacology + withdrawal review, 29 cases) ✓ PubMed
Comprehensive pharmacologic review: phenibut is a GABA-B agonist marketed as a nootropic/anxiolytic, legal and widely sold online in the USA without prescription. Across 29 withdrawal cases, patients were treated with baclofen, benzodiazepines and phenobarbital alone or combined; phenobarbital may be preferred over baclofen in patients at seizure risk. No comparative treatment studies exist and routine urine/plasma screening is unavailable.
Review Gurley & Koturbash 2024 (focused toxicology review) ✓ PubMed
Toxicology-focused review confirming phenibut acts at GABA-B and beta-phenethylamine receptors; intoxication, withdrawal and addiction can be life-threatening and require hospitalization. Ingestion is frequently combined with other substances of abuse, and management is hampered by absence of phenibut in standard drug-screening panels. Calls for adding phenibut to drug screens and developing accepted treatment protocols.
Review Jouney 2019 (review of dependence/addiction) ✓ PubMed
Review concluding that phenibut's pharmacology resembles a prescription-strength sedative rather than a nutritional supplement; multiple case reports document physical dependence, withdrawal and addiction, with intoxication ranging from minimal responsiveness to agitated delirium. Argues its 'dietary supplement' marketing is inaccurate and misleading given its GABA-B agonist profile.
Review Hardman, Sprung & Weingarten 2019 (literature review + case, 22 cases) ✓ PubMed
Literature review of 22 reported phenibut withdrawal cases plus an illustrative case: abrupt discontinuation precipitates an abstinence syndrome marked by severe psychomotor agitation that can mimic serotonin or neuroleptic malignant syndrome and requires aggressive multidrug pharmacologic treatment. Affected patients were typically younger with coexisting substance use disorders.
Analytical study 4 products tested ✓ PubMed
A 2022 Clinical Toxicology analysis found phenibut content in marketed 'supplement' products did not match labels — detected in two brands only after FDA warnings and increasing in three of four products, in one case reaching ~450% of a typical 250 mg pharmaceutical tablet.

Common questions about Phenibut

What is Phenibut used for?

Phenibut is most often marketed for Marketed for anxiety relief, but there are no rigorous, modern human trials demonstrating safe or effective use as a supplement — anxiolytic and sedative effects are mediated by GABA-B agonism but are unproven for any supplement claim and come with serious dependence risk., Promoted for sleep and as a nootropic/cognitive enhancer; these claims are unsupported by credible controlled human evidence and are outweighed by documented harms., Any short-term subjective calming or euphoric effect rapidly drives tolerance, escalating doses, and dependence rather than durable benefit.. A Soviet-era GABA-B drug sold online as a "calm" supplement — with a brutal dependence and withdrawal profile.

Does Phenibut work — what does the evidence say?

No Evidence evidence. No credible human evidence supports the marketed claims — widely considered ineffective. Phenibut (β-phenyl-GABA) is a central nervous system depressant developed in the Soviet Union that acts mainly as a GABA-B receptor agonist with additional gabapentinoid (α2δ calcium-channel) activity. It is sold online and in "supplement" or nootropic products for anxiety, sleep, and cognitive enhancement, but it is not approved as a dietary supplement or medicine in the US, UK, or Australia, and the FDA has stated it does not meet the definition of a dietary ingredient. There are no rigorous modern human trials supporting safe or effective supplement use, while a substantial case literature documents rapid tolerance, physical dependence, and a severe withdrawal syndrome that can include insomnia, hallucinations, agitation, delirium, and seizures, sometimes within hours of the last dose. Overdose — frequently involving co-ingested alcohol, benzodiazepines, or opioids — can cause profound sedation, reduced consciousness, agitated delirium, and cardiovascular and renal effects, with no specific antidote. Analyses have also found actual phenibut content in marketed products far exceeding label claims, compounding the risk. Given documented harms and absent credible benefit for its marketed claims, the evidence tier for safe supplement use is 'none'.

What is the typical dose of Phenibut?

No safe or approved supplement dose exists. Illicit recreational use is commonly 250–1500 mg, but dependent users escalate dramatically (case-series average ~13.6 g/day); not recommended at any dose.

Is Phenibut safe? Any cautions or side effects?

Not approved as a supplement or medicine in the US, UK, or Australia (banned/prohibited in Australia and restricted in several European countries). Phenibut produces rapid tolerance and physical dependence; abrupt cessation after regular use can cause a severe withdrawal syndrome — anxiety, insomnia, tremor, hallucinations, psychosis, autonomic instability, delirium, and seizures — that may require medically supervised baclofen or benzodiazepine tapering. Overdose causes deep sedation, reduced consciousness, agitation/delirium, low blood pressure, and renal impairment, with no specific antidote; high chronic intake (above ~7 g) has been linked to hepatic effects. Risk is greatly amplified by co-use with alcohol, benzodiazepines, opioids, or other CNS depressants — a common feature of reported toxicity and a potentially fatal combination. Marketed product potency is unreliable and often exceeds label claims, making dosing unpredictable. It must be avoided by anyone who is pregnant or breastfeeding, by people with a history of substance use disorder or psychiatric illness, and by those taking sedatives, GABAergics, or alcohol; do not stop established use abruptly — seek medical supervision.

How many studies support Phenibut?

NutriDex cites 13 sources for Phenibut, graded "No Evidence".

Does Phenibut interact with any medications?

Yes — known or theoretical interactions include: Sedatives (benzodiazepines, opioids, alcohol) (avoid). This is educational and not exhaustive; always check with your doctor or pharmacist before combining Phenibut with any medicine.

Cite this page
APA

Peh, D. (2026). Phenibut (β-phenyl-γ-aminobutyric acid): Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 26 Jun 2026, from https://nutridex.info/s/phenibut

BibTeX
@misc{nutridex_phenibut,
  author       = {Peh, Daryl},
  title        = {Phenibut (β-phenyl-γ-aminobutyric acid): Benefits, Dosage, Side Effects \& Evidence},
  year         = {2026},
  howpublished = {NutriDex --- The Supplement Research Compendium},
  url          = {https://nutridex.info/s/phenibut},
  note         = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-06-26}
}

For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.

← Back to the full dex · All substances